CIPLA : USFDA INSPECTION AT INVAGEN MANUFACTURING FACILITY

• Inspection conducted by USFDA at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA from July 13-17, 2026. • The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. • Company received 1 inspectional observation in Form 483. • Company will work closely with USFDA to address the observation. Impact: Neutral (Routine inspection yielded one observation, company committed to address it.)

Cipla Limited

Open attachment

← Back to feed